Evaluating The Efficacy Of Topical Losartan In Corneal Scar Management
Published 2025 - 43rd Congress of the ESCRS
Reference: PO1015 | Type: Poster | DOI: 10.82333/b6jg-2k30
Authors: Apeksha Manaklal Kataria* 1 , Rohit Shetty 2 , Gairik Kundu 1 , Pooja Khamar 2
1Cornea Refractive,Narayana Nethralaya,Bangalore,India, 2Refractive,Narayana Nethralaya,Bangalore,India
Purpose
To assess the clinical and imaging outcomes of patients with corneal scars treated with topical losartan (0.8 mg/mL) four times daily for three months.
Setting
A single-center prospective study conducted in a clinical research setting.
Methods
Ten eyes of ten patients (5 males, 5 females; mean age: 32.6 ± 4.6 years) were included. Patient demographics, scar etiology, duration, and previous topical treatments were recorded. Assessments were conducted at baseline, 1 month, and 3 months post-treatment. Clinical evaluation included uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA), refraction, slit-lamp examination, and corneal tomography. Scar depth and corneal densitometry were analyzed using the Pentacam® OCT (Oculus Optikgeräte GmbH). Drop comfort and any side effects were also documented
Results
At 3 months, the mean BCVA improved from 0.25 ± 0.17 to 0.17 ± 0.09 logMAR (p=0.12) in patients treated with losartan. Visual acuity improved in 6 eyes and remained unchanged in 4. A significant reduction in scar depth and corneal densitometry was noted in 5 eyes. No systemic side effects were reported.
Conclusions
Topical losartan may play a beneficial role in improving corneal clarity and reducing scar depth. While these preliminary findings are promising, further studies are necessary to fully evaluate its therapeutic potential.